Early diagnosis of pancreatic cancer: Challenges and new developments

Sukwinder Kaur, Michael J. Baine, Maneesh Jain, Aaron R. Sasson, Surinder Kumar Batra

Research output: Contribution to journalReview article

84 Citations (Scopus)

Abstract

Pancreatic cancer is a lethal malignancy with its incidence almost equivalent to mortality. The complex pathophysiology, absence of early diagnostic and prognostic markers and unresponsiveness to radiation and chemotherapies are major barriers against successful therapy. Poor performance of therapeutic agents, even in the initial stage of invasive cases, emphasizes the importance of early detection for improved survival. The present review discusses the challenges and advances in biomarkers including serological signatures, circulating tumor cells, autoantibodies, epigenetic markers and miRNAs that are being explored to detect this cancer at early stages. Considering the long time gap between the development of malignant lesions and full-blown primary and metastatic pancreatic cancer, unique opportunities are being contemplated for the development of potential diagnostic and prognostic markers.

Original languageEnglish (US)
Pages (from-to)597-612
Number of pages16
JournalBiomarkers in Medicine
Volume6
Issue number5
DOIs
StatePublished - Oct 1 2012

Fingerprint

Chemotherapy
Biomarkers
MicroRNAs
Pancreatic Neoplasms
Early Detection of Cancer
Autoantibodies
Tumors
Cells
Circulating Neoplastic Cells
Radiation
Epigenomics
Neoplasms
Drug Therapy
Mortality
Incidence
Therapeutics

Keywords

  • autoantibody
  • circulating tumor cell
  • imaging
  • pancreatic cancer
  • serological marker
  • tumor

ASJC Scopus subject areas

  • Drug Discovery
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Early diagnosis of pancreatic cancer : Challenges and new developments. / Kaur, Sukwinder; Baine, Michael J.; Jain, Maneesh; Sasson, Aaron R.; Batra, Surinder Kumar.

In: Biomarkers in Medicine, Vol. 6, No. 5, 01.10.2012, p. 597-612.

Research output: Contribution to journalReview article

@article{065d1c30bde4466f990f3d9df49fe56b,
title = "Early diagnosis of pancreatic cancer: Challenges and new developments",
abstract = "Pancreatic cancer is a lethal malignancy with its incidence almost equivalent to mortality. The complex pathophysiology, absence of early diagnostic and prognostic markers and unresponsiveness to radiation and chemotherapies are major barriers against successful therapy. Poor performance of therapeutic agents, even in the initial stage of invasive cases, emphasizes the importance of early detection for improved survival. The present review discusses the challenges and advances in biomarkers including serological signatures, circulating tumor cells, autoantibodies, epigenetic markers and miRNAs that are being explored to detect this cancer at early stages. Considering the long time gap between the development of malignant lesions and full-blown primary and metastatic pancreatic cancer, unique opportunities are being contemplated for the development of potential diagnostic and prognostic markers.",
keywords = "autoantibody, circulating tumor cell, imaging, pancreatic cancer, serological marker, tumor",
author = "Sukwinder Kaur and Baine, {Michael J.} and Maneesh Jain and Sasson, {Aaron R.} and Batra, {Surinder Kumar}",
year = "2012",
month = "10",
day = "1",
doi = "10.2217/bmm.12.69",
language = "English (US)",
volume = "6",
pages = "597--612",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Early diagnosis of pancreatic cancer

T2 - Challenges and new developments

AU - Kaur, Sukwinder

AU - Baine, Michael J.

AU - Jain, Maneesh

AU - Sasson, Aaron R.

AU - Batra, Surinder Kumar

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Pancreatic cancer is a lethal malignancy with its incidence almost equivalent to mortality. The complex pathophysiology, absence of early diagnostic and prognostic markers and unresponsiveness to radiation and chemotherapies are major barriers against successful therapy. Poor performance of therapeutic agents, even in the initial stage of invasive cases, emphasizes the importance of early detection for improved survival. The present review discusses the challenges and advances in biomarkers including serological signatures, circulating tumor cells, autoantibodies, epigenetic markers and miRNAs that are being explored to detect this cancer at early stages. Considering the long time gap between the development of malignant lesions and full-blown primary and metastatic pancreatic cancer, unique opportunities are being contemplated for the development of potential diagnostic and prognostic markers.

AB - Pancreatic cancer is a lethal malignancy with its incidence almost equivalent to mortality. The complex pathophysiology, absence of early diagnostic and prognostic markers and unresponsiveness to radiation and chemotherapies are major barriers against successful therapy. Poor performance of therapeutic agents, even in the initial stage of invasive cases, emphasizes the importance of early detection for improved survival. The present review discusses the challenges and advances in biomarkers including serological signatures, circulating tumor cells, autoantibodies, epigenetic markers and miRNAs that are being explored to detect this cancer at early stages. Considering the long time gap between the development of malignant lesions and full-blown primary and metastatic pancreatic cancer, unique opportunities are being contemplated for the development of potential diagnostic and prognostic markers.

KW - autoantibody

KW - circulating tumor cell

KW - imaging

KW - pancreatic cancer

KW - serological marker

KW - tumor

UR - http://www.scopus.com/inward/record.url?scp=84867646268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867646268&partnerID=8YFLogxK

U2 - 10.2217/bmm.12.69

DO - 10.2217/bmm.12.69

M3 - Review article

C2 - 23075238

AN - SCOPUS:84867646268

VL - 6

SP - 597

EP - 612

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 5

ER -